Glunor 850MG


Glunor 850MG


Stock Status:

In Stock



Metformin Hydrochloride



Treatment of type 2 diabetes mellitus, especially in overweight people, when food and exercise alone are unable to provide appropriate glycemic control.

  • Metformin can be used alone or in conjunction with other oral antidiabetic drugs or insulin in adults.
  • Metformin can be taken alone or in conjunction with insulin in children and adolescents as young as ten years old.

In overweight type 2 diabetic adult patients treated with metformin as first-line treatment following diet failure, there was a decrease in diabetes complications.n



Metformin is an antihyperglycemic medication of the biguanide class that is used to treat type 2 diabetes. Both baseline and postprandial plasma glucose levels are reduced. It has a different mode of action than sulfonylureas and does not cause hypoglycemia. Metformin increases insulin sensitivity by increasing peripheral glucose uptake and utilization. It lowers hepatic glucose production, lowers intestinal glucose absorption, and lowers hepatic glucose production.


Dosage & Administration

Metformin immediate release tablet: Dosage of Metformin Hydrochloride must be individualized on the basis of both effectiveness and tolerance, while not exceeding the maximum recommended daily doses.

  • Adult: The usual starting dose of Metformin is 500 mg twice a day or 850 mg once a day, given with meals. Dosage increases should be made in increments of 500 mg weekly or 850 mg every 2 weeks, up to a total of 2000 mg per day, given in divided doses. For those patients requiring additional glycemic control, Glucomin may be given to a maximum daily dose of 2550 mg per day. Doses above 2000 mg may be better tolerated given three times a day with meals.
  • Children: The usual starting dose of Metformin is 500 mg twice a day, given with meals. Dosage increases should be made in increments of 500 mg weekly up to a maximum of 2000 mg per day, given in divided doses.

Metformin extended release tablet: Swallow Metformin XR tablet whole and never crush, cut or chew.

  • Adult: The usual starting dose of Metformin XR is 500 mg once daily with the evening meal. Dose should be increased in increments of 500 mg weekly, up to a maximum of 2000 mg once daily with the evening meal, alternatively increased to 1000 mg twice daily taken with meal. Patient receiving Metformin immediate release tablet may be switched to Metformin extended release tablet up to a maximum recommended daily dose.
  • Children: Metformin extended release tablet has not been studied in children.
  • Renal impaired patient: Do not use Metformin in patients with eGFR below 30 mL/min/1.73 m2. Asses risk/benefit of counting if eGFR falls below 45 mL/min/1.73 m2.



Carbonic anhydrase (Topiramate, Zonisamide) co-administration may raise the risk of lactic acidosis. Drugs that decrease Metformin clearance (Ranolazine, Dolutegravir, Cimetidine) may cause Metformin buildup. Metformin’s effect on lactate metabolism can be amplified by alcohol.



  • Hypersensitivity to the active ingredient or any excipient.
  • Acute metabolic acidosis of any kind (such as lactic acidosis, diabetic ketoacidosis).
  • Renal failure with a GFR of less than 30 mL/min.
  • Dehydration, severe infection, and shock are examples of acute diseases that might affect renal function.
  • Acute or chronic diseases, such as cardiac or respiratory failure, recent myocardial infarction, shock, hepatic insufficiency, acute alcohol intoxication, and alcoholism, can induce tissue hypoxia.


Side Effect

Blood and lymphatic system disorders: Not known: Hemolytic anemia

Metabolism and nutrition disorders: Very rare: Lactic acidosis. Decrease of vitamin B12 absorption with a decrease of serum levels during long-term use of metformin. Consideration of such etiology is recommended if a patient presents with megaloblastic anemia. Cases of peripheral neuropathy in patients with vitamin B12 deficiency have been reported in post-marketing experience (frequency not known)

Nervous system disorders: Common: Taste disturbance. Not known: Encephalopathy

Gastrointestinal disorders: Very common: Gastrointestinal disorders, such as nausea, vomiting, diarrhea, abdominal pain, and loss of appetite. These undesirable effects occur most frequently during the initiation of therapy and resolve spontaneously in most cases. To prevent them, it is recommended that metformin be taken in 2 or 3 daily doses during or after meals. A slow increase of the dose may also improve gastrointestinal tolerability.

Hepatobiliary disorders: Very rare: Isolated reports of liver function test abnormalities or hepatitis resolving upon metformin discontinuation.

Skin and subcutaneous tissue disorders: Very rare: Skin reactions, such as erythema, pruritus, urticaria.


Pregnancy & Lactation

In individuals with hepatic impairment, gliclazide should be taken with caution. Gliclazide should not be taken if there is clear evidence of liver illness. Because gliclazide is thoroughly metabolized, it can be administered safely in individuals with renal failure. Gliclazide has a lower risk of hypoglycemia than the other sulfonylurea medications.

Metformin is secreted in human breast milk during breastfeeding. In breastfed newborns/infants, no harmful effects were found. Breastfeeding is not suggested when using metformin since there is insufficient data. The benefits of nursing and the possible danger of harmful effects on the kid should be considered while deciding whether or not to stop breastfeeding.


Precautions & Warnings

Metformin Hydrochloride is known to be eliminated in large amounts via the kidneys, and the danger of Metformin buildup and lactic acidosis rises as renal function declines. Metformin has been linked to a reduction in vitamin B12 levels. When combined with insulin or an insulin secretagogue, it raises the risk of hypoglycemia.


Therapeutic Class



Storage Conditions

Store in a cool and dry place, below 30°C and away from light.


Pharmaceutical Name

Eskayef Pharmaceuticals Ltd.